BioNTech and Pfizer said on Wednesday that a three-shot course of their Covid-19 vaccine was able to neutralise the new Omicron variant in a laboratory test and that they could deliver an Omicron-based vaccine in March 2022 if needed.
In the first official statement from vaccine manufacturers on the likely efficacy of their shot against Omicron, BioNTech and Pfizer said that two vaccine doses resulted in significantly lower neutralising antibodies but that a third dose of their vaccine increased the neutralising antibodies by a factor of 25.
Blood obtained from people who had their third booster shot a month ago neutralised the Omicron variant about as effectively as blood after two doses fought off the original virus first found in China.
"Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of Covid-19," Pfizer chief executive Albert Bourla said in the statement.
Covid vaccine approved for children aged 5-11 with rollout expected in January
EU expects Europe plants to produce 3.6 billion Covid shots in 2022
Johnson announces new Covid restrictions as he apologises for Downing Street video
Martin ‘one of fairest people’ in politics, says Varadkar amid row over booster comments
The findings are broadly in line with a preliminary study published by researchers at the Africa Health Research Institute in South Africa on Tuesday, saying that Omicron can partially evade protection from two doses of the Pfizer/BioNTech vaccine, suggesting also that a third shot might help fend off infection.
A lab analysis at the university hospital of Frankfurt, Germany, however found a reduced antibody response to Omicron even after three shots. - Reuters
